Fig. 3From: One-year prospective real-world assessment of effectiveness and safety of erenumab in migraine prevention: results of the French FHU INOVPAIN registry studyMedian with IQR of monthly migriane days (MMDs), monthly headache days (MHDs) and HIT6-score (HIT) at M0, M3, M6, M9 and M12Back to article page